Effects of positive psychological interventions on suicide-related outcomes: A systematic review and meta-analysis.

J Affect DisordJun 8, 2026 (epub)
Clinical ResearchPsychiatry

Xin-Yi Li, Ting Li, Jia-Hui Yan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of positive psychological interventions (PPIs) on suicide-related outcomes across 16 studies. The analysis found that PPIs were associated with a reduction in suicidal ideation (Hedges' g = -0.39, 95% CI: -0.74 to -0.04) at post-treatment, although evidence for longer-term effects and outcomes related to suicide attempts was limited.

Key findings

  • PPIs significantly reduced suicidal ideation with Hedges' g = -0.39.
  • Greater effects of PPIs were observed compared to waitlist/blank controls (Hedges' g = -0.63).
  • Preliminary evidence suggests PPIs combined with pharmacotherapy may reduce suicidal ideation more than pharmacotherapy alone (Hedges' g = -1.06).
  • Larger pooled effects were noted in low- and middle-income countries compared to high-income countries (p = 0.029).

Why it matters

Understanding the potential benefits of positive psychological interventions in reducing suicidal ideation can inform treatment strategies and contribute to suicide prevention efforts, particularly in diverse socioeconomic contexts.

Source

PubMed · PMID 42264312

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.